-
New advances in drugs. Best CP! Paboli Zuma Anti-Combination Rwantinib Treatment of Advanced Gastric Cancer ORR Up to 69%
Time of Update: 2020-07-19
The results showed that the objective remission rate of pabolizumab combined with rivatinib in the first and second line treatment of gastric cancer reached an amazing 69%!
-
TIGIT Target - Journey.
Time of Update: 2020-07-19
according to the article, the company's scientists found the target by combining two genome-wide search strategies: on the one hand, they selected genes with high specific expression on immune cells; on the other hand, they searched for genes with the structure of "extracellular immunoglobulin domain + type I transmembrane region + intracellular ITIM or tyrosine based activation motif".
-
2020 CSCO Guidelines for The Diagnosis and Treatment of Lymphoma in Children and Adolescents. Lymphoma of lymphoma.
Time of Update: 2020-07-19
during the meeting, Professor Hao Wenpeng of Harbin Institute of Hematology and oncology gave a detailed interpretation of the guidelines for diagnosis and treatment of lymphoblastic lymphoma in children and adolescents.
-
New findings: A genetic mutation unique to Brazilians increases their risk of cancer.
Time of Update: 2020-07-19
the researchers found that when a variant of the tumor suppressor gene XAF1 is combined with a genetic tp53-r337h mutation, the risk of cancer is increased.
Researchers at the University of St. Juda studied the causes of this variation by sequencing the whole genome of individuals of Brazilian origin.
-
22-year data on Chinese population: How much influence does tobacco and alcohol have on the risk of gastric cancer? I'm afraid it will offset other anti-cancer benefits...
Time of Update: 2020-07-19
screenshot: the yama network open Shandong intervention trial enrolled 3365 residents in Linqu County, a high incidence of gastric cancer, who received two weeks of Helicobacter pylori treatment (amoxicillin and omeprazole) and vitamin supplements (C, e and selenium) and garlic supplements (extracts and oils) or corresponding placebo controls for 7.3 years.
-
i Hope College . . . New advances in ASCO NSCLC joint therapy strategies.
Time of Update: 2020-07-19
Prof. Qin Haifeng: new progress of combined treatment strategy for ASCO NSCLC Professor: deputy chief physician and associate professor of pulmonary oncology department of cancer center of the fifth m
-
Cell: Seize the cancer 'metabolic weakness'! Real-time metabolic tracking and fat-free diet, tumor diagnosis and treatment of good efficacy.
Time of Update: 2020-07-19
specifically, in the latest study, scientists studied cancer cells and patient-derived tumors in the laboratory through iknife to look for "metabolic fingerprints", and then found a molecule called PI3K, which is crucial for the growth and survival of cancer cells and plays a key role in triggering the release of arachidonic acid (a key omega-6 fat).
-
Advances in genomics research on spinal tumors.
Time of Update: 2020-07-19
Chiropractic is a rare malignant tumor originating in the skull, spine and tibia, with low long-term survival rate and poor prognosis of nerve function After age adjustment, the incidence of spinal tu
-
Cross-border conversations . . . When an oncologist meets a cardiovascular doctor...
Time of Update: 2020-07-19
It includes four aspects: first, cardiovascular toxicity caused by drugs in the process of anti-tumor treatment, damage to the heart, etc., how to detect and early warn early, and how to intervene and treat.
-
Fat can destroy three generations! Obesity in mothers increases the risk of liver cancer in future generations.
Time of Update: 2020-07-19
recently, the Journal of In a new study published in Hepatology, a team led by Professor Zheng Ling, chief researcher of School of life sciences, Wuhan University, and Professor Huang Kun, affiliated Tongji School of pharmacy, Tongji Medical College, Huazhong University of science and technology, found that a microRNA in the mothers of obese mice seemed to be susceptible to liver cancer, thus increasing the possibility of their offspring and offspring suffering from liver cancer.
-
He had an "oral ulcer" and didn't expect to have chest surgery.
Time of Update: 2020-07-19
In the afternoon of the same day, the multidisciplinary team of Ruijin Hospital gathered, and experts from thoracic surgery, anesthesiology, critical care medicine, respiration and intervention departments gathered in the dermatology ward to analyze the possible diagnosis of the disease, the main contradictions at present, the advantages and disadvantages of the operation, the risks during and after the operation and the corresponding countermeasures.
-
ESMO-WCGI 2020. Early "dramatic": Apatinib in combination with TACE could bring potential benefits to patients with recurrent HCC.
Time of Update: 2020-07-19
the application of apatinib in the field of liver cancer can be traced back to 2014 American Society of Clinical Oncology (ASCO) conference, a phase II study published by Professor Qin Shukui showed that apatinib has potential survival benefits for patients with advanced HCC.
-
Progress in tumor-targeted superantigen research
Time of Update: 2020-07-19
relying on the Key Laboratory of super antigen research in Shenyang, the research group of microbial resources and ecology of Shenyang Institute of Applied Ecology, Chinese Academy of Sciences, is committed to the study of structure-activity relationship, structural transformation and development of immune and anti-tumor drugs.
-
The predictive value of the cancer embryo antigen binding fibrinogen/albumin ratio in removable gastric cancer.
Time of Update: 2020-07-19
univariate and multivariate Cox proportional regression model and Kaplan Meier survival curve were used to analyze the predictive role of the above laboratory indicators in the overall survival rate of patients with resectable gastric cancer.
-
2020 CSCO Guidelines for The Diagnosis and Treatment of Lymphoma in Children and Adolescents. Clinical application of high doses of methotrexate.
Time of Update: 2020-07-18
Theoretically, the PK / PD of 3hdmtx will not "rescue the tumor or over rescue" in theory For 24h infusion, the loading dose should be set according to different patients, so as to ensure that the plasma concentration of MTX can quickly reach a stable state during the follow-up infusion.
-
Heat ratio PD-1, CD19 target CAR-T, dual resistance, single resistance, ADC flowering.
Time of Update: 2020-07-18
at present, tafasitamab has been accepted by FDA and EMA for marketing in the United States (March 2, 2020) and Europe (May 20, 2020), and combined with lenalidomide for the treatment of patients with recurrent or refractory diffuse large B-cell lymphoma (R / R DLBCL).
-
Meeting Express . . . Navuliu mono-resistant: 240mg 30min is more convenient to administer!
Time of Update: 2020-07-18
The results of the checkmate 870 study confirmed the safety and reliability of the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) patients, mainly in Chinese population, with a fixed dose of 240 mg.
-
Tumor control of new antibodies: Multiple PD-1/L1 monoanti-rebatch solid tumor new indications, ADC for cervical cancer to seek accelerated approval of the new observation of the medicine.
Time of Update: 2020-07-18
on December 19, 2019, FDA accelerated the approval of padcev (enfortumab vedotin ejfv), an ADC drug jointly developed by Seattle genetics and Astellas, to be used in patients with locally advanced or metastatic urothelial carcinoma who have received PD-1 / L1 inhibitors and platinum based chemotherapy.
-
The late gastric cancer after the line "every life", DS-8201 strong effect to overcome front-line drug resistance! New advances in drugs.
Time of Update: 2020-07-18
in the phase I study of ds-8201 (ds8201-a-j101), the efficacy of 5.4mg or 6.4mg/kg was evaluated in 44 patients with her positive gastric cancer or gastroesophageal junction cancer after trastuzumab treatment.
-
Antibody drug coupling new model! New company received about $100 million in financing to advance the HER2-plus solid tumor clinical trial.
Time of Update: 2020-07-18
in the press release, the new round of financing will support the continuous clinical development of its leading ISAC bdc-1001, which is currently used as a monotherapy for cancer expressing HER2; and support the company boltbody Gamma Expanded treatment pipeline platform.
